US Patent Issued to MYELOPRO DIAGNOSTICS AND RESEARCH on Sept. 9 for "Compounds targeting mutant calreticulin" (Austrian Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,185, issued on Sept. 9, was assigned to MYELOPRO DIAGNOSTICS AND RESEARCH GmbH (Vienna).

"Compounds targeting mutant calreticulin" was invented by Oleh Zagrijtschuk (Vienna) and Ruochen Jia (Vienna).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such compounds as well as to their use in treating diseases or conditions caused by or associated with a mutation of CALR, in particular myeloid malignancies, such as myeloproliferati...